Use of Neurotrophic Factor-alpha1/Carboxypeptidase E (CPE) to Treat Alzheimer Disease
Summary:
The NICHD is seeking licensees for development of Carboxypeptidase E (CPE) as a therapy for MCI or AD.
Treatment of Periodontal Disease via ENPPI Inhibition
This technology focuses on enhancing cementum production, a key component in treating periodontal regression. The method involves inhibiting ectonucleotide pyrophosphatase phosphodiesterases (ENPP1), enzymes that play a significant role in mineralization processes. Pyrophosphate (PPi) is known to impede the growth of hydroxyapatite crystals, essential for mineralization. ENPP1 catalyzes the hydrolysis of ATP, generating PPi, which then hinders mineralization.
Replication-Competent VSV–BDBV Vaccine for Rapid Prevention and Post- Exposure Protection Against Bundibugyo Virus
Bundibugyo virus (BDBV) is one of several ebolaviruses that cause Ebola virus disease (EVD). Sporadic outbreaks continue to occur in Central Africa, highlighting the need for effective vaccines that provide rapid protection.
RP2 and RPGR Vectors For Treating X-linked Retinitis Pigmentosa
X-linked forms of retinitis pigmentosa (XLRP) are relatively severe blinding disorders, resulting from progressive photoreceptor dysfunction primarily caused by mutations in RPGR or RP2 gene.
Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees to develop a collection of anti-CE1 antibodies for liver cancer treatment.
Quantitative Particle Identification (QPID) Digital Autoradiography System
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a Quantitative Particle Identification (QPID) digital autoradiography system with particle identification capabilities.
Monoclonal Antibody (RO4) that Reacts with the Juxta-membrane Region of Mesothelin
Summary:
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers.
Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Summary:
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in-class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis.
Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy
Summary:
Scientists at the National Cancer Institute (NCI) have developed a novel tightly regulated drug-responsive, membrane-bound IL-12 cytokine platform, that enhances anti-tumor efficacy in adoptive cell therapy (ACT) with engineered T-cells (CAR, TCR, TILs) while improving safety. The NCI seeks research co-development partners and/or licensees to advance this technology toward clinical translation.
Combined RNA and DNA Vaccination Strategy for Improving the Vaccine Immune Response
Description of Technology:
The development of an effective HIV vaccine has been ongoing. HIV sequence diversity and immunodominance are major obstacles in the design of an effective vaccine. Researchers at the National Cancer Institute (NCI) developed a novel vaccine strategy combining both DNA and mRNA vaccination to induce an effective immune response. This combination strategy could also be used to develop vaccines against cancer or other infectious diseases (ex. SARS-CoV-2).